Savara Inc (SVRA) Quote

SVRA under $5

SVRA under $5

SVRE fresh nazy with volume

SVRA.......................https://stockcharts.com/h-sc/ui?s=SVRAp=W&b=5&g=0&id=p86431144783

SVRA new 52 week high

SVRA................................https://stockcharts.com/h-sc/ui?s=SVRA&p=W&b=5&g=0&id=p86431144783

SVRA...................https://stockcharts.com/h-sc/ui?s=SVRA&p=W&b=5&g=0&id=p86431144783

SVRA.................................https://stockcharts.com/h-sc/ui?s=SVRAp=W&b=5&g=0&id=p86431144783

SVRA.................................https://stockcharts.com/h-sc/ui?s=SVRA&p=W&b=5&g=0&id=p86431144783

Impala must be doing better ... hod $2.82 been making nice moves during last few days!

Wake up call to the board $2.47

Finally done dumping on the new financials. Looks like consolidation and ??????

Looking for comments,
What some see as a dump, others see as an opportunity.
What say you?

Wow looks like dump is still on imo

Check out what BARCHART has to say about SVRA

Barchart Technical Opinion
STRONG BUY
The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

jumped in, looks good to me

Savara Inc Stock may give you a sharp bounce - svra stock



Last Ratings
3/16/2021 Piper Sandler Initiated Coverage Overweight $7.00 High
3/15/2021 Oppenheimer Initiated Coverage Outperform $4.00 High

Not really, had 120 million volume yesterday
But volume is far about average and chart is building!
Many big institutional investors, plus company insiders holding big positions.

The volume today should say it all, surpassed yesterdays volume in the first 30 minutes.

Looks like they still at it

This is one you need for long term. Just warming up. My price target is $5-10!

Corrupt MM's manipulation brought it down from the highs yesterday's.

Jep, 100% agree. It traded volume of a whole year on one day while insiders have been buying. For reason imo

Closed a massive 130 mill Offering! Check out the AH filings! This will run soon!!

* * $SVRA Video Chart 03-16-2021 * *

Link to Video - click here to watch the technical chart video

In the money Jan. 6: Drug, burger makers report multimillion-dollar fundings

..................................

• Savara Inc. has raised about $26.8 million as it develops drugs to treat rare lung diseases. The Austin-based pharmaceutical company announced Dec. 20 it intended to sell more than 9.5 million shares of common stock and pre-funded warrants to buy more than 5.7 million shares in a private placement with "institutional investors," which would generate the $26.8 million, although Savara (Nasdaq: SVRA) still needs to deduct placement agent fees and other offering expenses. The company filed securities paperwork Jan. 2 indicating it had raised the $26.8 million from 18 investors. Savara said Dec. 20 it has also agreed to sell warrants that could allow investors to buy more than 32.5 million additional shares of common stock. The warrants can be exercised by investors two years after the close of this private placement or 30 days after Savara achieves a certain clinical milestone, whichever is earlier. That sale could raise gross proceeds of $48.2 million, according to the company, before deducting expenses and fees. Bain Capital Life Sciences led the placement and Ricky Sun of Bain Capital has joined Savara's board of directors. Investors in the private placement included EcoR1 Capital LLC and Logos Capital. Founded in 2008, Savara is led by CEO Rob Neville and develops drugs for orphan lung diseases such as autoimmune pulmonary alveolar proteinosis and nontuberculous mycobacteria.
https://www.bizjournals.com/austin/news/2020/01/06/in-the-money-jan-6-drug-burger-makers-report.html?ana=yahoo&yptr=yahoo


GO SVRA

"PEACE"

DMOST....."In Like Flint", look towards a huge pay day down the road, in a relatively short time frame.

Are Options Traders Betting on a Big Move in Savara (SVRA) Stock?

Investors in Savara Inc. SVRA need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2020 $5.00 Call had some of the highest implied volatility of all equity options today.

What is Implied Volatility?

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?

Clearly, options traders are pricing in a big move for Savara shares, but what is the fundamental picture for the company? Currently, Savara is a Zacks Rank #3 (Hold) in the Medical - Drugs industry that ranks in the Top 23% of our Zacks Industry Rank. Over the last 30 days, one analyst has increased the earnings estimate for the current quarter, while none have dropped their estimates. The net effect has narrowed our Zacks Consensus Estimate for the current quarter from a loss of 52 cents per share to a loss of 49 cents in that period.

Given the way analysts feel about Savara right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
https://finance.yahoo.com/news/options-traders-betting-big-move-143002217.html

GO SVRA

"PEACE"

* * $SVRA Video Chart 01-02-2020 * *

Link to Video - click here to watch the technical chart video

* * $SVRA Video Chart 12-31-2019 * *

Link to Video - click here to watch the technical chart video

So. We buying calls or puts? 5 strikes.

We never lose taking profits.

I'm waiting for the right moment to get back in. It will probably not be today. I also have 2 other stocks on my radar that I have been following, and investing in, for awhile. US*W*S and AU**XX*F

What’s the offering price?

You were alerted at 2.30 multiple times bud.

Looks like run is over here. Needs consolidate

I did the same damn thing:


I sold too soon for a decent profit but should have held on for a day or two.

$$Nice move up today. Congrats.
5.7400 +0.83 (16.90%)
After hours: 7:59PM EST

I got it - sold too soon.

Was so glad to make a buck, sold way too soon. I will get back in tomorrow after seeing the after hours action and the Bain Capital's 9.9% stake.

Their latest presentation is worth a listen Savara

An understanding is that the Impala trial would have passed if not for a small group of 4 in the placebo group who use oxygen. Their use of oxygen is necessary, and they were allowed to use oxygen during the actual 6 minute walk. The rate of oxygen they used during the walk increased due to the exertion necessary, this raised the placebo groups score.

Would appreciate any feedback...

http://ih.advfn.com/stock-market/NASDAQ/savara-SVRA/stock-news/81434794/current-report-filing-8-k

http://ih.advfn.com/stock-market/NASDAQ/savara-SVRA/stock-news/81438175/statement-of-beneficial-ownership-sc-13d

http://ih.advfn.com/stock-market/NASDAQ/savara-SVRA/stock-news/81434542/savara-granted-breakthrough-therapy-designation-fo

"....The Molgradex Breakthrough Therapy designation is based on data from IMPALA, a pivotal Phase 3 clinical study evaluating Molgradex for the treatment of aPAP. Data from the study was recently presented in an oral session at the 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain.

“We are pleased that the FDA recognized Molgradex as a breakthrough therapy for the treatment of aPAP, a debilitating rare lung disease with no approved pharmacologic treatment options,” said Rob Neville, Chief Executive Officer, Savara. “We believe this designation reflects the significance of Molgradex as an investigational product that, based on the IMPALA study, has been demonstrated to improve patient outcomes. Breakthrough designation is designed to provide increased collaboration and more frequent dialogue with the FDA and is an important milestone as we work to determine the best path forward for this product.”

About Savara

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3-stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/)....."

over 6 buks now

So far this evening, the $3.50 area is proving to have been a prescient reload point for Round Two. Another double waiting in the wings? We'll know soon enough.....

Go to the presentations on SVRA website

* * $SVRA Video Chart 12-30-2019 * *

Link to Video - click here to watch the technical chart video

Wow

I think $5 break is coming right up.

it is going to make a run to $5.



could open at $6 tomorrow.

WOW smoking hot on FDA approval

here we go people:


$4 break is coming right up.

Looks like there will be a short squeeze here.

This is going up bigly.

This is fixing to make another explosive jump.

Can easily close at $4.50 to $5